Related Experiment Video
Updated: Jan 18, 2026

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
Published on: June 30, 2021
AAV-Based Gene Therapy: Opportunities, Risks, and Scale-Up Strategies
Daniil Moldavskii1, Zarema Gilazieva1, Alisa Fattakhova1
1Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
None:
Currently, the development of adeno-associated virus (AAV)-based gene therapy is a promising method for treating various diseases and is gaining increasing popularity. However, the use of AAV has certain drawbacks and faces limitations such as immune responses and an increased risk of insertional mutagenesis, which have not always been adequately considered in the context of AAV therapy. Moreover, a significant limitation for the application of AAV lies in the challenge of producing it in large quantities. This article discusses the use of AAV in treating various diseases, reviews AAV production approaches, highlights challenges with insufficient viral titers during production, and explores potential solutions at key stages of AAV drug production.
More Related Videos
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
Published on: October 18, 2022
07:43Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
Related Concept Videos
Gene Therapy
Microorganisms in Medicine and Therapeutics
Preclinical Development: Overview